comparemela.com

Latest Breaking News On - Cancer research annual meeting - Page 12 : comparemela.com

Faron s Financial Statement Release January 1 to December 31, 2023 -March 13, 2024 at 03:01 am EDT

TURKU, Finland and BOSTON, March 13, 2024 Faron Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies,.

United statesFred hutchinson cancer research centerJo turnerChristine rothJames obrienLeopoldo zambelettiSandy jamiesonJuha karttunenDavid daleyGregoryb brownMary jane elliottMarkku jalkanenBirge bernsChristopher goldenLindsey nevilleAnne whitaker

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Highe.

United statesNorth carolinaConor richardsonMirvetuximab soravtansineTaylor schreiberAmerican society of hematologyExchange commissionShattuck labs incCancer researchOno pharmaceutical co ltdHealth care conference bostonDevelopment rd expensesRna work in cancer researchHigher risk myelodysplastic syndromesAcute myeloid leukemiaAmerican society

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine in frontline Higher-Risk Myelodysplastic Syndromes and frontline TP53 mutant.

United statesNorth carolinaTaylor schreiberConor richardsonMirvetuximab soravtansineCancer researchRna work in cancer researchShattuck labs incOno pharmaceutical co ltdExchange commissionDevelopment rd expensesHealth care conference bostonAmerican society of hematologyHigher risk myelodysplastic syndromesAcute myeloid leukemiaAmerican society

RenovoRx CEO Issues Letter to Shareholders

Recent financing will drive Company towards second interim analysis on pivotal Phase III TIGeR-PaC clinical trial by end of 2024 .

Shaunr bagaiShaun bagaiData monitoring committeeRenovorx incExchange commissionCompany nasdaqSecurities exchangeChief executive officerFellow renovorx shareholdersTrans arterial micro perfusionOverall survivalCancer research annual meetingLate breaker oral presentationMedical oncology world congressGastrointestinal cancerNew drug application

RenovoRx CEO Issues Letter to Shareholders

RenovoRx, Inc. ("RenovoRx" or the "Company") , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer,.

Shaun bagaiShaunr bagaiSecurities exchangeExchange commissionData monitoring committeeCompany nasdaqRenovorx incChief executive officerFellow renovorx shareholdersTrans arterial micro perfusionOverall survivalCancer research annual meetingLate breaker oral presentationMedical oncology world congressGastrointestinal cancerNew drug application

vimarsana © 2020. All Rights Reserved.